Welcome Guest
Home » Reports » Cancer Metabolism Based Therapeutics, 2017-2030

Cancer Metabolism Based Therapeutics, 2017-2030

Published: Apr 21, 2017
Pages: 263
Product Code: RA10080
License Type :  (Learn More)

Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the observation that metabolic activity in tumor tissues leads to a ten-fold increase in production of lactate (from glucose) under aerobic conditions. This revelation generated a significant interest and led industry stakeholders to target metabolic pathways in an effort to find the treatment of cancer. In addition, several academic players have also initiated studies to explore the functional consequences of alterations in various metabolic pathways.

 

The idea behind therapeutic strategies that target cancer metabolism is to limit / modulate the supply of crucial nutrients in cancer cells in order to induce cell death. Over the years, experimental and conceptual advances in this field have resulted in a better understanding of the role of metabolic pathways for the treatment of cancer. Owing to the complex nature of these pathways, innovation in this domain has been gradual. However, the knowledge that metabolic adaptations in cancer cells promote their malignant properties has led to the development of novel therapeutic approaches for cancer treatment; selective inhibition of altered metabolic pathways in cancer cells is believed to be a highly promising approach.

 

Currently, there are several molecules that are under preclinical and clinical evaluation. Extensive research is currently being carried out to explore the potential of certain enzymes of metabolic pathways to act as targets for the treatment of cancer. The alterations in metabolic pathways in cancer cells are often mediated by mutations in oncogenes and cell signaling pathways. However, with the recognition of specific enzymes within each metabolic pathway, it is anticipated that drugs targeting these enzymes are likely to have high efficacy in treating cancer with minimal side-effects.

 

Despite the fact that the field of cancer metabolism therapeutics is still in early stages, there are many active players in this area. A larger proportion of players (on the basis of number of molecules) are small-sized and start-up companies. In fact, well-known big pharma companies have come together with smaller players to support discovery and development of such therapies. Our research indicates that there are several players with mid / late-stage clinical candidates that are likely to enter the market in the coming decade; examples include Agios Pharmaceuticals, Celgene, Polaris Group, Bio-Cancer Treatment International, BERG Health, Cornerstone Pharmaceuticals, Taiho Pharmaceutical, Novartis and 3-V Biosciences.

 

A number of strategic and research collaborations have been inked between companies to progress research activities in this area. As clinical stage candidates progress towards advanced stages of development and companies continue to receive monetary support from different stakeholders, we expect an aggressive growth to unfold over the coming years.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The Cancer Metabolism Based Therapeutics Market, 2017-2030 report provides an extensive study on the current landscape of the emerging pipeline of novel drugs that target metabolic pathways in cancer cells and offers a comprehensive discussion on the likely future potential.

 

The primary focus is on drugs that lead to metabolic reprogramming in cancer cells by altering / inhibiting the activity of key enzymes / transporters that are a part of glucose metabolism, amino acid metabolism, TCA cycle, lipid metabolism, nucleotide metabolism and pentose phosphate pathway. The scope includes novel products that are being specifically developed to target altered metabolic pathways and key enzymes / amino acids involved in the metabolism of cancer cells. Examples of such enzymes / amino acids include isocitrate dehydrogenase 1 mutant (IDH 1), arginine, glutamine, MTH1, L-type amino acid transporter 1 (LAT1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB3), choline kinase (ChoK), glucose transporter-1 (Glut-1) and hexokinase II. Specifically, certain drugs based on amino acid metabolism are being developed under the class of immuno-oncology drugs; these have been excluded from the scope of this document.

 

The overall pipeline comprises of 48 molecules that are under development for the treatment of a variety of oncological indications. Of these, 20 molecules are undergoing clinical evaluation while others (28) are in discovery / preclinical stages. This unexploited and promising market has its hopes pinned on multiple start-ups and small-sized companies, which have received significant financial support from strategic investors and venture capital firms in the recent past. Amongst other elements, the report provides information on:

  • The current state of the market with respect to key players, phase of development of pipeline products (both clinical and preclinical / discovery), target enzymes / metabolic pathways and the key disease indications.
  • Comprehensive profiles of the clinical stage (phase III, phase II/III, phase II, phase II (planned)) molecules highlighting details on development of the drug, clinical trials, clinical trial endpoints, key preclinical / clinical findings, developer details including their financial performance (if available) and future market opportunity.
  • Various investments and grants received by companies focused in this area in order to accelerate and support their R&D activities.
  • Partnerships that have taken place in the recent past covering product development / commercialization agreements, research collaborations, clinical trial collaborations, license agreements, mergers / acquisitions and other such deals signed between stakeholders in the industry or with non-industrial players.
  • Distribution of the pipeline through a schematic funnel analysis, an overview of the landscape of industry developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of cancer metabolism therapeutics.
  • Key targets, shortlisted based on dot-plot analysis, three-dimensional bubble analysis and five-dimensional spider-web analysis. Relevant parameters such as number of publications, grant programs, number of clinical trials, phase of development, and number of companies developing drugs for specific targets were considered for these analyses.

 

One of the key objectives of this report was to understand the current activity and the future potential of the market. The study provides a detailed market forecast and opportunity analysis from 2017 to 2030. The research, analysis and insights presented in this report are backed by a detailed understanding of the therapies targeting cancer metabolism and other targets closely associated with them. To account for uncertaintiesassociated with the development of novel therapeutics and add robustness to our model, we have provided three scenarios for our market forecast, namely the conservative, base and optimistic scenarios. All actual figures have been sourced and analyzed from publicly available information forums and from primary research. All financial figures mentioned in this report are in USD, unless otherwise specified.

 

Example Highlights

  1. Of the total drugs targeting cancer metabolism, ~40% are being investigated in clinical stages of development.Examples of late-stage drugs include enasidenib (awaiting FDA approval), ivosidenib (phase III), ADI-PEG 20 (phase II/III), BCT-100 (phase II), BPM 31510 (phase II), CPI-613 (phase II), TAS-114 (phase II), IDH305 (phase II (planned)) and TVB-2640 (phase II (planned)).
  2. Glycolysis, the most primitive pathway utilized by cancer cells to harness their energy requirement, has been extensively researched. It is followed by amino acid metabolism. Both these pathways capture over 20% of the pipeline each. TCA cycle is the third most popular pathway and accounts for 17% of the overall development pipeline.
  3. During our research, we identified over 35 companies that are actively engaged in the development of drugs that target enzymes involved in various metabolic pathways. The overall market is distributed across different regions; majority of the players are located in the US (61%), followed by Germany (16%) and the UK (5%). Further, around 63% of the total companies we identified are small-sized players; examples include (in alphabetical order) 3-V Biosciences, Advanced Cancer Therapeutics, Aeglea BioTherapeutics, Bio-Cancer Treatment International, Calithera Biosciences, Cornerstone Pharmaceuticals, J Pharma, New Medical Enzymes, Polaris Group and Translational Cancer Drugs Pharma. Mid-sized players that are active in this area include Agios Pharmaceuticals, BERG Health, Forma Therapeutics and vTv Therapeutics. Established players that are actively involved in the development of both preclinical and clinical candidates include (in alphabetical order) AstraZeneca, Bayer, Celgene, Daiichi Sankyo, Genentech, Gilead Sciences, Merck KGaA, Novartis, Selvita and Taiho Pharmaceutical.
  4. Several academic / research institutes are also conducting extensive R&D activities in this field. Examples of such institutes include (in alphabetical order) Cancer Research Technology (part of Cancer Research UK), European Molecular Biology Laboratory, Ludwig Institute for Cancer Research, MD Anderson Cancer Center, National Cancer Institute (NCI), University of Florida, University of Louisville’s James Graham Brown Cancer Center, Wake Forest University and Weill Cornell Medical College.
  5. Close to 40 deals have been signed over the last decade; these encompass product development and / or commercialization agreements (over 33%), research collaborations (26%), license agreements (20%), clinical trial collaborations (10%) and mergers / acquisitions (10%). In fact, several companies have entered into multiple collaborations; examples include Agios Pharmaceuticals, Celgene, Advanced Cancer Therapeutics, Merck KGaA, Polaris Group, AstraZeneca, BERG Health, Calithera Biosciences, Cornerstone Pharmaceuticals, FORMA Therapeutics, Janssen Biotech, Selvita and Sprint Bioscience.
  6. Angel investors, venture capitalists and funding programs of various other organizations have provided monetary assistance to start-ups / small companies to pace up their R&D programs. Notably, close to USD 1.3 billion has been invested in this domain over the past few years.
  7. With several promising candidates in the pipeline, the cancer metabolism based therapeutics market is expected to prosper in the long term; our outlook is highly optimistic as we expect the emergence of several successful drugs in the coming decade. Post the launch of the first wave of products, we anticipate the field to witness considerable success and grow at an annualized rate of ~100% till 2030.

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and sub-segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on the current state of the cancer metabolism based therapeutics market and its likely evolution in the mid-long term.

 

Chapter 3 provides a general introduction to the underlying concepts of cancer metabolism, emphasizing on the role of disrupting metabolic pathways in cancer cells. The chapter covers detailed information on the Warburg effect, mechanism of key metabolic pathways (amino acid metabolism, lipid metabolism, nucleotide metabolism, pentose phosphate pathway and TCA   cycle), the role of target enzymes within each pathway and the challenges associated with targeting metabolic pathways. We have also provided a list of key targets that have been the focus of industry players.

 

Chapter 4 provides a comprehensive overview of the current landscape of the cancer metabolism based therapeutics market. It includes information on the drug candidates that are currently in different stages of development (both clinical and preclinical / discovery) and presents a detailed analysis of the pipeline products on the basis of target indications, therapeutic area, phase of development, type of molecule, target enzymes, route of administration and key players involved in this space.

 

Chapter 5 contains detailed profiles of the drugs that are being evaluated in advanced stages of clinical development (phase III, phase II/III, phase II, phase II (planned)). Each profile features a general overview of the drug and provides information on additional aspects, such as number of clinical trials, key clinical trial endpoints, clinical trial results, and an overview, financial performance and future outlook of the developer.

 

Chapter 6 provides a comprehensive market forecast, highlighting the future potential of the market till 2030. It includes future sales projections of molecules in phase III, phase II/III, phase II and phase II (planned) of development. The sales potential and growth opportunity is based on the target patient populations, existing / future competition, and the likely adoption rates and price points.

 

Chapter 7 presents details on the investments and grants received by the companies working in the field of cancer metabolism. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.

 

Chapter 8 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this segment of the overall market.

 

Chapter 9 is a compilation of certain key insights gained from the study. It features an analysis of the landscape of developers (small, mid-sized and large companies) that are active in this area and their geographical presence. It also provides a schematic representation highlighting the distribution of pipeline drugs and the targeted metabolic pathway within the field of cancer metabolism. We have also included a clinical validation analysis that was conducted to highlight the most popular targets / pathways based on the number of publications, grant programs, clinical trials, phase of development, and number of companies developing drugs for each target.

 

Chapter 10 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways from the study and our independent opinion based on the research and analysis described in previous chapters.

 

Chapter 11 is a collection ofinterview transcript(s) of the discussion(s) held with stakeholders in the field of cancer metabolism.

 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 13 is an appendix, which provides the list of companies and organizations mentioned in the report.

 

 

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cellular Metabolism: An Introduction
3.3. Cancer Cell Metabolism: An Introduction
3.4. Cancer Cell Metabolism: History and Evolution
3.5. Altered Metabolic Pathways in Cancer Cells
3.5.1. Glucose Metabolism
3.5.2. TCA Cycle
3.5.3. Amino Acid Metabolism
3.5.3.1. Glutamine Metabolism
3.5.3.2. Arginine Metabolism
3.5.3.3. Serine and Glycine Metabolism
3.5.4. Nucleotide Metabolism
3.5.5. Pentose Phosphate Pathway
3.5.6. Lipid Metabolism
3.6. Challenges Associated with Targeting Metabolic Pathways
3.7. Targeting Altered Metabolic Pathways for Cancer Treatment
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cancer Metabolism Based Therapeutics: Clinical Pipeline
4.3. Cancer Metabolism Based Therapeutics: Preclinical Pipeline
4.4. Cancer Metabolism Based Therapeutics: Distribution by Phase of Development
4.5. Cancer Metabolism Based Therapeutics: Distribution by Targeted Metabolic Pathway
4.6. Cancer Metabolism Based Therapeutics: Distribution by Target
4.7. Cancer Metabolism Based Therapeutics: Distribution by Type of Molecule
4.8. Cancer Metabolism Based Therapeutics: Distribution by Therapeutic Area
4.9. Cancer Metabolism Based Therapeutics: Distribution by Indication
4.10. Cancer Metabolism Based Therapeutics: Distribution by Route of Administration
4.11. Cancer Metabolism Based Therapeutics: Distribution by Key Players
4.12. Cancer Metabolism Based Therapeutics: Distribution by Headquarters of Developers
4.13. Cancer Metabolism Based Therapeutics: Role of Non-Industry Players
 
5. DRUG PROFILES
5.1. Chapter Overview
5.2. Enasidenib / AG-221 (Agios Pharmaceuticals)
5.2.1. Overview
5.2.2. Mechanism of Action
5.2.3. Current Status of Development
5.2.4. Clinical Studies
5.2.5. Preclinical / Clinical Findings
5.2.5.1. Preclinical Data
5.2.5.2. Clinical Data
5.2.6. Agios Pharmaceuticals
5.2.6.1. Overview
5.2.6.2. Financial Performance
5.2.6.3. Future Outlook
 
5.3. Ivosidenib / AG-120 (Agios Pharmaceuticals)
5.3.1. Overview
5.3.2. Mechanism of Action
5.3.3. Current Status of Development
5.3.4. Clinical Studies
5.3.5. Preclinical / Clinical Findings
5.3.5.1. Preclinical Data
5.3.5.2. Clinical Data
5.3.6. Agios Pharmaceuticals
5.3.6.1. Overview
5.3.6.2. Financial Performance
5.3.6.3. Future Outlook
 
5.4. ADI-PEG 20 (Polaris Group)
5.4.1. Overview
5.4.2. Mechanism of Action
5.4.3. Current Status of Development
5.4.4. Clinical Studies
5.4.5. Preclinical / Clinical Findings
5.4.5.1. Preclinical Data
5.4.5.2. Clinical Data
5.4.6. Polaris Group
5.4.6.1. Overview
5.4.6.2. Future Outlook
 
5.5. BCT-100 (Bio-Cancer Treatment International)
5.5.1. Overview
5.5.2. Mechanism of Action
5.5.3. Current Status of Development
5.5.4. Clinical Studies
5.5.5. Preclinical / Clinical Findings
5.5.5.1. Preclinical Data
5.5.5.2. Clinical Data
5.5.6. Bio-Cancer Treatment International
5.5.6.1. Overview
5.5.6.2. Future Outlook
 
5.6. BPM 31510 (BERG Health)
5.6.1. Overview
5.6.2. Mechanism of Action
5.6.3. Current Status of Development
5.6.4. Clinical Studies
5.6.5. Preclinical / Clinical Findings
5.6.5.1. Preclinical Data
5.6.5.2. Clinical Data
5.6.6. BERG Health
5.6.6.1. Overview
5.6.6.2. Technology Platform: Interrogative Biology®
5.6.6.3. Future Outlook
 
5.7. CPI-613 (Cornerstone Pharmaceuticals)
5.7.1. Overview
5.7.2. Mechanism of Action
5.7.3. Current Status of Development
5.7.4. Clinical Studies
5.7.5. Preclinical / Clinical Findings
5.7.5.1. Preclinical Data
5.7.5.2. Clinical Data
5.7.6. Cornerstone Pharmaceuticals
5.7.6.1. Overview
5.7.6.2. Financial Performance
5.7.6.3. Future Outlook
 
5.8. TAS-114 (Taiho Pharmaceutical)
5.8.1. Overview
5.8.2. Mechanism of Action
5.8.3. Current Status of Development
5.8.4. Clinical Studies
5.8.5. Preclinical / Clinical Findings
5.8.5.1. Preclinical Data
5.8.5.2. Clinical Data
5.8.6. Taiho Pharmaceutical
5.8.6.1. Overview
5.8.6.2. Financial Performance
5.8.6.3. Future Outlook
 
5.9. IDH305 (Novartis)
5.9.1. Overview
5.9.2. Mechanism of Action
5.9.3. Current Status of Development
5.9.4. Clinical Studies
5.9.5. Preclinical / Clinical Findings
5.9.6. Novartis
5.9.6.1. Overview
5.9.6.2. Financial Performance
5.9.6.3. Future Outlook
 
5.10. TVB 2640 (3-V Biosciences)
5.10.1. Overview
5.10.2. Mechanism of Action
5.10.3. Current Status of Development
5.10.4. Clinical Studies
5.10.5. Preclinical / Clinical Findings
5.10.5.1. Preclinical Data
5.10.5.2. Clinical Data
5.10.6. 3-V Biosciences
5.10.6.1. Overview
5.10.6.2. Financial Performance
5.10.6.3. Future Outlook
 
6. MARKET FORECAST AND OPPORTUNITY ANALYSIS
6.1. Chapter Overview
6.2. Scope and Limitations
6.3. Forecast Methodology
6.4. Overall Cancer Metabolism Based Therapeutics Market (USD Million)
6.5. Cancer Metabolism Based Therapeutics Market: Individual Drug Forecasts (USD Million)
 
6.5.1. Enasidenib (Agios Pharmaceuticals)
6.5.1.1. Target Patient Population
6.5.1.2. Sales Forecast
 
6.5.2. Ivosidenib (Agios Pharmaceuticals)
6.5.2.1. Target Patient Population
6.5.2.2. Sales Forecast
 
6.5.3. ADI-PEG 20 (Polaris Group)
6.5.3.1. Target Patient Population
6.5.3.2. Sales Forecast
 
6.5.4. BPM 31510 (BERG Health)
6.5.4.1. Target Patient Population
6.5.4.2. Sales Forecast
 
6.5.5. CPI-613 (Cornerstone Pharmaceuticals)
6.5.5.1. Target Patient Population
6.5.5.2. Sales Forecast
 
6.5.6. BCT-100 (Bio-Cancer Treatment International)
6.5.6.1. Target Patient Population
6.5.6.2. Sales Forecast
 
6.5.7. IDH305 (Novartis)
6.5.7.1. Target Patient Population
6.5.7.2. Sales Forecast
 
6.5.8. TAS-114 (Taiho Pharmaceutical)
6.5.8.1. Target Patient Population
6.5.8.2. Sales Forecast
 
6.5.9. TBV-2640 (3-V Biosciences)
6.5.9.1. Target Patient Population
6.5.9.2. Sales Forecast
 
7. VENTURE CAPITAL INTEREST
7.1. Chapter Overview
7.2. Cancer Metabolism Based Therapeutics: List of Funding Instances
7.2.1. Cancer Metabolism Based Therapeutics: Cumulative Number of Investments by Year, Pre 2010-2017
7.2.2. Cancer Metabolism Based Therapeutics: Cumulative Amount Invested by Year, Pre 2010-2017 (USD Million)
7.2.3. Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding
7.2.4. Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players
7.2.5. Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Venture Capital Firms / Investors
 
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cancer Metabolism Based Therapeutics: Recent Partnerships
8.3.1. Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Year (2006-2017)
8.3.2. Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Type of Model
8.3.3. Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Product / Focus Area
8.3.4. Cancer Metabolism Based Therapeutics: Leading Collaborators
 
9. KEY INSIGHTS
9.1. Chapter Overview
9.2. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Developer Landscape
9.3. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Targeted Metabolic Pathway, Phase of Development and Type of Molecule
9.4. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Geographical Presence of Companies
9.5. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Popularity of Metabolic Enzymes / Targets
 
10. CONCLUSION
10.1. Growing Understanding of Tumor Associated Metabolic Alterations has Advanced the Field of Cancer Metabolism
10.2. Commercialization of Late-Stage Drugs and Advancement of Discovery / Preclinical Candidates in the Near Future is Likely to Sustain the Momentum
10.3. Amongst Various Metabolic Pathways, Amino Acid Metabolism and Glucose Metabolism Have Been Most Widely Researched
10.4. Small Pharmaceutical Companies are Emerging as Key Players; Research is Heavily Concentrated in the US and Parts of Europe
10.5. Growing Partnerships and Venture Capital Support are Indicative of Lucrative Future Potential
10.6. Once Approved, Cancer Metabolism Based Therapeutics are Poised to Achieve an Accelerated Growth
 
11. INTERVIEW TRANSCRIPTS
11.1. Chapter Overview
11.2. Raul Mostoslavsky, Associate Professor, Medicine, Harvard Medical School
11.3. Magdalena Marciniak, Business Alliance Manager, Selvita S.A.
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
 

 

Figure 3.1 Key Metabolic Pathways in Normal Cells
 
Figure 3.2 Factors Affecting Cancer Cell Metabolism
 
Figure 3.3 Fundamentals of Warburg Effect
 
Figure 3.4 Glucose Metabolism in Cancer Cells
 
Figure 3.5 TCA Cycle in Cancer Cells
 
Figure 3.6 Glutamine Metabolism in Cancer Cells
 
Figure 3.7 Arginine Metabolism in Cancer Cells
 
Figure 3.8 Serine and Glycine Metabolism in Cancer Cells
 
Figure 3.9 Pentose Phosphate Pathway in Cancer Cells
 
Figure 3.10 Lipid Metabolism in Cancer Cells
 
Figure 3.11 Lipid Metabolism in Cancer Cells: Altered Steps
 
Figure 4.1 Cancer Metabolism Based Therapeutics: Distribution by Phase of Development
 
Figure 4.2 Cancer Metabolism Based Therapeutics: Distribution by Targeted Metabolic Pathway
 
Figure 4.3 Cancer Metabolism Based Therapeutics: Distribution by Target
 
Figure 4.4 Cancer Metabolism Based Therapeutics: Distribution by Type of Molecule
 
Figure 4.5 Cancer Metabolism Based Therapeutics: Distribution by Therapeutic Area
 
Figure 4.6 Cancer Metabolism Based Therapeutics: Distribution by Indication
 
Figure 4.7 Cancer Metabolism Based Therapeutics: Distribution by Route of Administration
 
Figure 4.8 Cancer Metabolism Based Therapeutics: Distribution by Key Players
 
Figure 4.9 Cancer Metabolism Based Therapeutics: Distribution by Headquarters of Developers
 
Figure 5.1 Agios Pharmaceuticals: Revenues, 2011-2016 (USD Million)
 
Figure 5.2 Agios Pharmaceuticals: Funding Instances, 2008-2016 (USD Million)
 
Figure 5.3 BERG’s Interrogative Biology® Platform: Disease Areas
 
Figure 5.4 Cornerstone Pharmaceuticals: Funding Instances, 2009-2016 (USD Million)
 
Figure 5.5 Taiho Pharmaceutical: Revenues, 2011-2015 (JPY Billion)
 
Figure 5.6 Novartis: Revenues, 2011-2016 (USD Billion)
 
Figure 5.7 3-V Biosciences: Funding Instances, 2007-2016 (USD Million)
 
Figure 6.1 Overall Cancer Metabolism Based Therapeutics Market, 2017-2030: Base Scenario (USD Million)
 
Figure 6.2 Cancer Metabolism Based Therapeutics Market (USD Million), 2021, 2025 and 2030 (Base Scenario): Distribution by Drugs and Metabolic Pathways
 
Figure 6.3 Enasidenib Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.4 Ivosidenib Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.5 ADI-PEG 20 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.6 BPM 31510 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.7 CPI-613 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.8 BCT-100 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.9 IDH305 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.10 TAS-114 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 6.11 TVB-2640 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.1 Cancer Metabolism Based Therapeutics: Cumulative Number of Investments by Year, Pre 2007-2017
 
Figure 7.2 Cancer Metabolism Based Therapeutics: Cumulative Amount Invested by Year, Pre 2007-2017 (USD Million)
 
Figure 7.3 Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding
 
Figure 7.4 Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding and Amount Invested (USD Million)
 
Figure 7.5 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players by Number of Instances
 
Figure 7.6 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players by Amount Invested (USD Million)
 
Figure 7.7 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Venture Capital Firms / Investors
 
Figure 8.1 Cancer Metabolism Based Therapeutics: Cumulative Number of Partnerships by Year (2006-2017)
 
Figure 8.2 Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Type of Model
 
Figure 8.3 Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Product / Focus Area
 
Figure 8.4 Cancer Metabolism Based Therapeutics: Leading Collaborators
 
Figure 9.1 Cancer Metabolism Based Therapeutics Developer Landscape: Distribution by Developer and Phase of Development
 
Figure 9.2 Cancer Metabolism Based Therapeutics Funnel Analysis: Distribution by Targeted Metabolic Pathway, Phase of Development and Type of Molecule
 
Figure 9.3 Cancer Metabolism Based Therapeutics: Geographical Presence of Companies
 
Figure 9.4 Cancer Metabolism Based Therapeutics: Bubble Analysis for Targets Undergoing Clinical Evaluation
 
Figure 9.5 Cancer Metabolism Based Therapeutics: Spider-Web Analysis for Targets Undergoing Clinical Evaluation
 
Figure 9.6 Cancer Metabolism Based Therapeutics: Dot-Plot Analysis for Targets Undergoing Preclinical Evaluation
 
Figure 10.1 Cancer Metabolism Based Therapeutics Market, 2017, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Million)
 

 

Table 3.1 Role of Key Metabolic Pathways in Normal Cells
 
Table 3.2 Cancer Metabolism Based Therapeutics: List of Key Metabolic Enzymes / Targets
 
Table 4.1 Cancer Metabolism Based Therapeutics: Clinical Pipeline
 
Table 4.2 Cancer Metabolism Based Therapeutics: Preclinical Pipeline
 
Table 4.3 Cancer Metabolism Based Therapeutics: List of Non-Industry Players
 
Table 5.1 Cancer Metabolism Based Therapeutics: Key Molecules Under Development
 
Table 5.2 Enasidenib: Current Status of Development
 
Table 5.3 Enasidenib: Clinical Trials
 
Table 5.4 Enasidenib: Clinical Trial Endpoints for Hematological Malignancies and Solid Tumors
 
Table 5.5 Ivosidenib: Current Status of Development
 
Table 5.6 Ivosidenib: Clinical Trials
 
Table 5.7 Ivosidenib: Clinical Trial Endpoints for Hematological Malignancies and Solid Tumors
 
Table 5.8 ADI-PEG 20: Current Status of Development
 
Table 5.9 ADI-PEG 20: Clinical Trials
 
Table 5.10 ADI-PEG 20: Clinical Trial Endpoints for Solid Tumors (Phase I)
 
Table 5.11 ADI-PEG 20: Clinical Trial Endpoints for Solid Tumors (Phase II, Phase II/III and Phase III)
 
Table 5.12 ADI-PEG 20: Clinical Trial Endpoints for Hematologic Malignancies (Phase I and Phase II)
 
Table 5.13 BCT-100: Current Status of Development
 
Table 5.14 BCT-100: Clinical Trials
 
Table 5.15 BCT-100: Clinical Trial Endpoints for Hematological Malignancies and Solid Tumors
 
Table 5.16 BPM 31510: Current Status of Development
 
Table 5.17 BPM 31510: Clinical Trials
 
Table 5.18 BPM 31510: Clinical Trial Endpoints for Solid Tumors
 
Table 5.19 CPI-613: Current Status of Development
 
Table 5.20 CPI-613: Clinical Trials
 
Table 5.21 CPI-613: Clinical Trial Endpoints for Hematological Malignancies
 
Table 5.22 CPI-613: Clinical Trial Endpoints for Solid Tumors
 
Table 5.23 TAS-114: Current Status of Development
 
Table 5.24 TAS-114: Clinical Trials
 
Table 5.25 TAS-114: Clinical Trial Endpoints for Solid Tumors
 
Table 5.26 IDH305: Current Status of Development
 
Table 5.27 IDH305: Clinical Trials and Endpoints for Solid Tumors
 
Table 5.28 TVB 2640: Current Status of Development
 
Table 5.29 TVB 2640: Clinical Trials
 
Table 5.30 TVB 2640: Clinical Trial Endpoints for Solid Tumors
 
Table 6.1 Cancer Metabolism Based Therapeutics: Expected Launch Year 
 
Table 6.2 Enasidenib: Target Patient Population
 
Table 6.3 Ivosidenib: Target Patient Population
 
Table 6.4 ADI-PEG 20: Target Patient Population
 
Table 6.5 BPM 31510: Target Patient Population
 
Table 6.6 CPI-613: Target Patient Population
 
Table 6.7 BCT-100: Target Patient Population
 
Table 6.8 IDH305: Target Patient Population
 
Table 6.9 TAS-114: Target Patient Population
 
Table 6.10 TVB-2640: Target Patient Population
 
Table 7.1 Cancer Metabolism Based Therapeutics: List of Funding Instances and Investors
 
Table 7.2 Cancer Metabolism Based Therapeutics: Types of Funding Instances
 
Table 8.1 Cancer Metabolism Based Therapeutics: Recent Partnerships
 
Table 9.1 Cancer Metabolism Based Therapeutics: Bubble Analysis for Targets Undergoing Clinical Evaluation
 
Table 9.2 Cancer Metabolism Based Therapeutics: Spider-Web Analysis for Targets Undergoing Clinical Evaluation
 
Table 9.3 Cancer Metabolism Based Therapeutics: Dot Plot Analysis for Targets Undergoing Preclinical Evaluation
 
Table 12.1 Cancer Metabolism Based Therapeutics: Distribution by Phase of Development
 
Table 12.2 Cancer Metabolism Based Therapeutics: Distribution by Target Metabolic Pathway
 
Table 12.3 Cancer Metabolism Based Therapeutics: Distribution by Target
 
Table 12.4 Cancer metabolism Based Therapeutics: Distribution by Type of Molecule
 
Table 12.5 Cancer Metabolism Based Therapeutics: Distribution by Therapeutic Area
 
Table 12.6 Cancer Metabolism Based Therapeutics: Distribution by Indication
 
Table 12.7 Cancer Metabolism Based Therapeutics: Distribution by Route of Administration
 
Table 12.8 Cancer Metabolism Based Therapeutics: Distribution by Key Players
 
Table 12.9 Cancer Metabolism Based Therapeutics: Distribution by Headquarters of Developers
 
Table 12.10 Agios Pharmaceuticals: Revenues, 2011-2016 (USD Million)
 
Table 12.11 Agios Pharmaceuticals: Funding Instances, 2008-2016 (USD Million)
 
Table 12.12 Cornerstone Pharmaceuticals: Funding Instances, 2009-2016 (USD Million)
 
Table 12.13 Taiho Pharmaceutical: Revenues, 2011-2015 (JPY Billion)
 
Table 12.14 Novartis: Revenues, 2011-2016 (USD Billion)
 
Table 12.15 3-V Biosciences: Funding Instances, 2007-2016 (USD Million)
 
Table 12.16 Overall Cancer Metabolism Based Therapeutics Market, 2017-2030: Base Scenario (USD Million)
 
Table 12.17 Overall Cancer Metabolism Based Therapeutics Market, 2017-2030: Optimistic Scenario (USD Million)
 
Table 12.18 Overall Cancer Metabolism Based Therapeutics Market, 2017-2030: Conservative Scenario (USD Million)
 
Table 12.19 Cancer Metabolism Based Therapeutics Market (USD Million), 2021, 2025 and 2030 (Base Scenario): Distribution by Drugs and Metabolic Pathways
 
Table 12.20 Cancer Metabolism Based Therapeutics Market (USD Million), 2021, 2025 and 2030 (Optimistic Scenario): Distribution by Drugs and Metabolic Pathways
 
Table 12.21 Cancer Metabolism Based Therapeutics Market (USD Million), 2021, 2025 and 2030 (Conservative Scenario): Distribution by Drugs and Metabolic Pathways
 
Table 12.22 Enasidenib Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.23 Enasidenib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.24 Enasidenib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.25 Ivosidenib Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.26 Ivosidenib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.27 Ivosidenib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.28 ADI-PEG 20 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.29 ADI-PEG 20 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.30 ADI-PEG 20 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.31 BPM 31510 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.32 BPM 31510 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.33 BPM 31510 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.34 CPI-613 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.35 CPI-613 Sales Forecast (Tiil-2030): Optimistic Scenario (USD Million)
 
Table 12.36 CPI-613 Sales Forecast (Tiil-2030): Conservative Scenario (USD Million)
 
Table 12.37 BCT-100 Sales Forecast (Tiil-2030): Base Scenario (USD Million)
 
Table 12.38 BCT-100 Sales Forecast (Tiil-2030): Optimistic Scenario (USD Million)
 
Table 12.39 BCT-100 Sales Forecast (Tiil-2030): Conservative Scenario (USD Million)
 
Table 12.40 IDH305 Sales Forecast (Tiil-2030): Base Scenario (USD Million)
 
Table 12.41 IDH305 Sales Forecast (Tiil-2030): Optimistic Scenario (USD Million)
 
Table 12.42 IDH305 Sales Forecast (Tiil-2030): Conservative Scenario (USD Million)
 
Table 12.43 TAS-114 Sales Forecast (Tiil-2030): Base Scenario (USD Million)
 
Table 12.44 TAS-114 Sales Forecast (Tiil-2030): Optimistic Scenario (USD Million)
 
Table 12.45 TAS-114 Sales Forecast (Tiil-2030): Conservative Scenario (USD Million)
 
Table 12.46 TVB-2640 Sales Forecast (Tiil-2030): Base Scenario (USD Million)
 
Table 12.47 TVB-2640 Sales Forecast (Tiil-2030): Optimistic Scenario (USD Million)
 
Table 12.48 TVB-2640 Sales Forecast (Tiil-2030): Conservative Scenario (USD Million)
 
Table 12.49 Cancer Metabolism Based Therapeutics: Cumulative Number of Investments by Year, Pre 2010-2017
 
Table 12.50 Cancer Metabolism Based Therapeutics: Cumulative Amount Invested by Year, Pre 2010-2017 (USD Million)
 
Table 12.51 Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding
 
Table 12.52 Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding and Amount Invested (USD Million)
 
Table 12.53 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players by Number of Instances
 
Table 12.54 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players by Amount Invested (USD Million)
 
Table 12.55 Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Venture Capital Firms / Investors
 
Table 12.56 Cancer Metabolism Based Therapeutics: Cumulative Number of Partnerships by Year (2006-2017)
 
Table 12.57 Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Type of Model
 
Table 12.58 Cancer Metabolism Based Therapeutics: Distribution of Partnerships by Product / Focus Area
 
Table 12.59 Cancer Metabolism Based Therapeutics: Leading Collaborators
 
Table 12.60 Cancer Metabolism Based Therapeutics Market, 2017, 2023, 2030: Conservative, Base and Optimistic Scenarios (USD Million)
 
  1. 2M Companies
  2. 3-V Biosciences
  3. Abbott
  4. Accelerate Brain Cancer Cure
  5. Adage Capital Partners
  6. Ade Capital Sodical SCR
  7. Admune Therapeutics
  8. Advanced Cancer Therapeutics
  9. Advanced Technology Ventures
  10. Aeglea BioTherapeutics
  11. Agios Pharmaceuticals
  12. Aju Tech
  13. Alexandria Venture Investments
  14. Ally Bridge Group
  15. Althea Partners
  16. American Association for Cancer Research
  17. American Society for Radiation Oncology
  18. American Society of Clinical Oncology
  19. American Society of Hematology
  20. ARCH Venture Partners
  21. Arkin Holdings
  22. Astellas Venture Management
  23. AstraZeneca
  24. Atlas Venture
  25. Barts Cancer Institute
  26. Bayer
  27. Becton Dickinson
  28. BERG Health
  29. BIND Therapeutics
  30. Bio-Cancer Treatment International
  31. BioMed X
  32. Boehringer Ingelheim Venture Fund
  33. Boston College
  34. Bristol Myers Squibb
  35. Calithera Biosciences
  36. Cancer Research Technology
  37. Cancer Research UK
  38. Celgene
  39. Chinese University of Hong Kong
  40. Ciba-Geigy
  41. Clave Mayor
  42. Cloud Pharmaceuticals
  43. Commonwealth Capital Ventures
  44. Conegliano Ventures
  45. Cornerstone Pharmaceuticals
  46. Cowen Group
  47. CRB Inverbio
  48. Daiichi Sankyo
  49. Dana-Farber Cancer Institute
  50. Delphi Ventures
  51. DesigneRx Pharmaceuticals
  52. Emory University
  53. Encore Vision
  54. European Hematology Association
  55. European Medicines Agency
  56. European Molecular Biology Laboratory
  57. European Organisation for Research and Treatment of Cancer
  58. European Society of Medical Oncology
  59. Flagship Ventures
  60. Food and Drug Administration
  61. FORMA Therapeutics
  62. Foundation Medicine
  63. Genentech
  64. German Cancer Research Center
  65. Gilead Sciences
  66. GNTech
  67. Grifols
  68. Harvard Medical School
  69. Hong Kong Department of Health
  70. Horizon Discovery
  71. IDT Corporation
  72. ImmunoMet Therapeutics
  73. Informa
  74. International Mesothelioma Interest Group
  75. IOmet Pharma
  76. J Pharma
  77. Janssen Biotech
  78. Jennison Associates
  79. Kancera
  80. Kantar Health
  81. Karolinska Institutet
  82. KBI Biopharma
  83. Kentucky Science and Technology Corporation
  84. Kleiner Perkins Caufield & Byers
  85. Kyushu University
  86. Lightstone Ventures
  87. Lilly Ventures
  88. Lo Ka Chung Centre for Natural Anti-Cancer Drug Development
  89. Longwood Fund
  90. Louisiana State University
  91. Ludwig Institute for Cancer Research
  92. Mary Crowley Cancer Research Centers
  93. Massachusetts General Hospital Cancer Center
  94. MD Anderson Cancer Center
  95. Medical University of Vienna
  96. Medidata Solutions
  97. Memorial Sloan Kettering Cancer Center
  98. Merck KGaA
  99. Metabomed
  100. MetaVest
  101. Mirae Asset Venture Investment
  102. Mission Bay Capital
  103. Moleculin
  104. Morgenthaler Ventures
  105. MPM Capital
  106. MS Ventures
  107. National Cancer Institute
  108. National Institutes of Health
  109. New Enterprise Associates
  110. New Medical Enzymes
  111. New York University School of Medicine
  112. Nimbus Therapeutics
  113. Northwestern University
  114. Novartis
  115. Novartis Venture Fund
  116. Novo
  117. Ohio State University
  118. Oncotherapeutics
  119. OrbiMed
  120. Ostuka Holdings
  121. Partikula
  122. Partners Innovation Fund
  123. Pfizer
  124. Polaris Group
  125. Polaris Pharmaceuticals
  126. Pontifax
  127. Princeton University
  128. Queen Mary Hospital
  129. Quintiles
  130. RA Capital Management
  131. Raze Therapeutics
  132. Rgenix
  133. Rock Springs Capital
  134. Rutgers Cancer Institute of New Jersey, Rutgers University
  135. Sandoz
  136. Selexys Pharmaceuticals
  137. Selvita
  138. Sofinnova Partners
  139. Spinifex Pharmaceuticals
  140. Sprint Bioscience
  141. Stand Up To Cancer
  142. Stanford University
  143. Stanford University School of Medicine
  144. Stockholm University
  145. Sylvester Comprehensive Cancer Center
  146. Taiho Oncology
  147. Taiho Pharmaceutical
  148. Taiho Ventures
  149. TAVARGENIX
  150. TDW Group
  151. TDW Pharmaceuticals
  152. Technion Research & Development Foundation
  153. Telix Pharmaceuticals
  154. The Abramson Family Foundation
  155. The Chetrit Group
  156. The Column Group
  157. The Francis Crick Institute
  158. The Hong Kong Polytechnic University
  159. Therapeia
  160. Third Rock Ventures
  161. TPP Global Development
  162. Translational Cancer Drugs (TCD) Pharma
  163. University of Birmingham
  164. University of Bologna
  165. University of California
  166. University of Chicago
  167. University of Florida
  168. University of Hong Kong
  169. University of Kentucky
  170. University of Louisville’s James Graham Brown Cancer Center
  171. University of Miami
  172. University of Miami Leonard M. Miller School of Medicine
  173. University of Michigan
  174. University of Pennsylvania
  175. University of Texas Health Science Center
  176. University of Texas Southwestern Medical Center
  177. US Venture Partners
  178. UT Horizon Fund
  179. Venrock
  180. vTv Therapeutics
  181. Wake Forest University
  182. Weill Cornell Medical College
  183. Wilson Sonsini Goodrich & Rosati
  184. Windhover Information
  185. Ziarco Group

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security